TGA Issues $126,720 in Penalties Over Prescription Medicine Imports and Advertising
06 Oct 2026
The notices relate to products including prescription medicines advertised without authorisation, unapproved melatonin products, Mounjaro pens, erectile dysfunction medicines and cosmetic injectable products. The penalties were paid between July and September 2026.
The Australian Centre for Functional Medicine Pty Ltd received three notices totalling $59,400 over the alleged importation of unapproved melatonin products. Chan and Khin Pty Ltd and a Queensland-based health practitioner received four notices totalling $47,520 relating to the advertising of prescription medicines, including lovastatin, baricitinib and ketamine.
The remaining notices involved individuals in Victoria and New South Wales over the alleged importation of prescription medicines and cosmetic injectables.
Professor Anthony Lawler, head of the TGA, said importing or advertising therapeutic goods outside Australia's regulatory requirements could put public health at risk.
Medicines generally need to be included in the Australian Register of Therapeutic Goods (ARTG) before they can be legally imported, advertised or supplied, unless an exemption or other authorisation applies. Products not assessed by the TGA may pose risks to consumers.
The TGA said advertising prescription-only medicines could encourage inappropriate demand and influence treatment decisions without proper medical guidance. Businesses and individuals are responsible for meeting their legal obligations, with possible consequences including penalties and prosecution.
TGA Issues $126,720 in Penalties Over Prescription Medicine Imports and Advertising